Jefferies analyst David Windley maintained a Hold rating on Catalent (CTLT – Research Report) today and set a price target of $63.50.

Jupiter Neurosciences, Inc. (JUNS) is planning to raise $11 million in an initial public offering (IPO) on the week of November 11th, IPO Scoop reports. The company plans to issue 2,800,000 shares at ...

Welcome to the third-quarter 2024 Novo Nordisk A/S earnings conference call. [Operator instructions] Please be advised that ...

Jupiter Neurosciences, Inc. (JUNS) is planning to raise $11 million in an IPO on the week of November 4th, IPO Scoop reports. The company will be issuing 2,800,000 shares at a price of $4.00 per share ...

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, ...

A Catalent spokesperson reiterated the ... but said that the drugmaker has secured near-term supplies for its clinical trials of the GLP-1 drugs it is developing. Roche plans to manage the scaling ...

Viatris Inc. today announced that on November 4, 2024, its Board of Directors declared a quarterly dividend of $0.12 per share for each issued and outstanding share of the Company's common stock. The ...

Adicet Bio, Inc. , a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced acceptance of an oral ...

NEW YORK (Reuters) -U.S. consumer groups and two large labor unions urged the U.S. Federal Trade Commission on Thursday to block Novo Holdings, the controlling shareholder of Novo Nordisk, from ...